A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study With Open-Label Follow-up to Investigate the Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men
Latest Information Update: 24 May 2024
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism; Metabolic syndrome
- Focus Pharmacodynamics
- Acronyms Moscow
- 23 May 2024 Results describing changes in homeostasis model assessment of insulin resistance index (HOMA-IR) following testosterone therapy in men with hypogonadism and metabolic syndrome (MetS), published in the Diabetes, Obesity and Metabolism
- 13 May 2010 Interim results were presented at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy).
- 09 Jul 2008 New trial record.